share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  08/14 15:35
Moomoo AI 已提取核心訊息
Aclarion, Inc., a healthcare technology company, reported financial results for the quarter ended June 30, 2024. Revenue for the quarter was $10,971, a decrease from $17,072 in the same period last year. The company experienced a gross loss of $12,323 compared to a loss of $2,229 in the previous year, primarily due to the conclusion of certain clinical activities. Operating expenses totaled $1,123,238, with a decrease in general and administrative expenses from $946,175 to $696,099. The net loss for the quarter was $1,238,077, an improvement from a net loss of $1,464,557 in the prior year. The company's cash position, including restricted cash, was $1,182,687, which is expected to fund operations into the third quarter of 2024. Aclarion's future plans include raising additional funds to continue technology development, with management actively seeking funding options. The company's financial statements reflect the impact of a reverse stock split and the issuance of new shares through a public offering and an equity line agreement.
Aclarion, Inc., a healthcare technology company, reported financial results for the quarter ended June 30, 2024. Revenue for the quarter was $10,971, a decrease from $17,072 in the same period last year. The company experienced a gross loss of $12,323 compared to a loss of $2,229 in the previous year, primarily due to the conclusion of certain clinical activities. Operating expenses totaled $1,123,238, with a decrease in general and administrative expenses from $946,175 to $696,099. The net loss for the quarter was $1,238,077, an improvement from a net loss of $1,464,557 in the prior year. The company's cash position, including restricted cash, was $1,182,687, which is expected to fund operations into the third quarter of 2024. Aclarion's future plans include raising additional funds to continue technology development, with management actively seeking funding options. The company's financial statements reflect the impact of a reverse stock split and the issuance of new shares through a public offering and an equity line agreement.
醫療科技公司艾克萊里昂公佈了截至2024年6月30日的季度財務報告。該季度營業收入爲10,971美元，較去年同期的17,072美元有所下降。公司毛損失爲12,323美元，相比上一年的2,229美元虧損，主要是由於某些臨床活動的結束。營業費用總額爲1,123,238美元，其中一般和行政費用降至696,099美元，而上年同期爲946,175美元。該季度的淨虧損爲1,238,077美元，較前一年的1,464,557美元的淨虧損有所改善。公司的現金頭寸，包括受限現金在內，爲1,182,687美元，預計可以支持運營到2024年第三季度。艾克萊里昂未來的計劃包括籌集額外的資金以繼續科技的開發，管理層積極尋求籌資選擇。公開發行和股權額度協議發行新股以及股票拆分對公司的財務報表產生了影響。
醫療科技公司艾克萊里昂公佈了截至2024年6月30日的季度財務報告。該季度營業收入爲10,971美元，較去年同期的17,072美元有所下降。公司毛損失爲12,323美元，相比上一年的2,229美元虧損，主要是由於某些臨床活動的結束。營業費用總額爲1,123,238美元，其中一般和行政費用降至696,099美元，而上年同期爲946,175美元。該季度的淨虧損爲1,238,077美元，較前一年的1,464,557美元的淨虧損有所改善。公司的現金頭寸，包括受限現金在內，爲1,182,687美元，預計可以支持運營到2024年第三季度。艾克萊里昂未來的計劃包括籌集額外的資金以繼續科技的開發，管理層積極尋求籌資選擇。公開發行和股權額度協議發行新股以及股票拆分對公司的財務報表產生了影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息